Skip to main content
Premium Trial:

Request an Annual Quote

Diversigen, Crohn's & Colitis Foundation Partner for Metagenomics, Microbiome Analysis Services

NEW YORK (GenomeWeb) – Diversigen announced today that the Crohn's & Colitis Foundation has selected the firm as a preferred provider for metagenomics and microbiome analysis services, as well as to serve as a central lab for generating and incorporating microbiome data into the foundation's IBD Plexus platform.

The IBD Plexus research information exchange platform centralizes data and biosamples from diverse research initiatives as part of the foundation's efforts to drive precision medicine and remodel IBD patient care.

The partnership will allow academic and industry researchers access to Diversigen's microbiome analytical capabilities, ensuring that they use the same protocols and pipelines, which is important for creating uniform and reproducible datasets.

"Engaging large cohorts with optimized standard practices is fundamentally critical for discovery in translational microbiome research," Diversigen Founder and CSO Joseph Petrosino said in a statement. "The inclusion of such data into the IBD Plexus platform is a model for research across many areas of disease."

"Through our partnership with Diversigen, we are converting finite biosamples into reusable assets that will enable researchers across the country to not only gain expedited access to molecular data, but also leverage uniform datasets across projects," IBD Plexus Senior Director Angela Dobes said in a statement.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.